Abstract:

Currently OSAS is recognized as an independent predictor for obesity, and this, in turn, is characterized as the main risk factor for OSAS. This article aims to review the existing literature on the relationship between OSA and obesity, whereas endocrine and metabolic aspects of this relationship and to discuss the role of weight loss in the treatment of this syndrome. Several studies have shown that OSA is directly associated with endocrine disorders such as leptin levels and ghrelin, hormones related to hunger and satiety, and can contribute to increased insulin resistance and cortisol, increasing the risk of chronic diseases such as cardiovascular. Whereas OSAS is an independent risk factor for hypertension and cardiovascular disease, as well as being strongly associated with obesity and insulin resistance, various treatments have been currently proposed, including surgery, oral appliances, CPAP use, as well as changes in lifestyle, which focus on inclusion of exercise and decreased calorie intake, which promotes the reduction of anthropometric measurements and improvement in AHI and respiratory parameters. It is concluded that OSA and obesity trigger endocrine and metabolic disorders, which can negatively affect the health of the individual. Thus, it can be said that the reduction of body mass is clinically important for obese patients with OSAS and should be a measure of important attention in the treatment of this disease.

Keywords: